Tools
Tools
Cybulska, B, Kłosiewicz-Latoszek, L, Penson, PE, Nabavi, SM, Lavie, CJ, Banach, M and International Lipid Expert Panel (ILEP), (2020) How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors. Progress in Cardiovascular Diseases. ISSN 0033-0620
|
Text
How low should you go with LDL cholesterol lowering in secondary prevention.pdf - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (517kB) | Preview |
Abstract
There is a strong evidence that more marked lowering of low-density lipoprotein cholesterol (LDL-C) leads to progressively lower risk of cardiovascular disease (CVD) events. The evidence on validity of this hypothesis comes from epidemiological, genetic and clinical studies. The hypothesis "the lower the better" has been recently strongly supported by the results of secondary prevention trials with PCSK9 inhibitors. The combination of PCSK9 inhibitors and statins has resulted in achieving extremely low LDL-C levels with additional reduction of CVD events in secondary prevention. However, despite large clinical benefits, the safety of aggressive LDL-C lowering should be always taken into consideration, and there is still an ongoing discussion on whether very low LDL-C might result in some non-CVD adverse events. However, based on the available knowledge, so far the serious adverse events associated with achieving of very low LDL-C levels or intensive drug therapy have not been noted. These positive clinical effects were reflected in current ESC/EAS Guidelines (2019) for dyslipidaemia management. The experts strongly recommended the LDL-C lowering to levels that have been achieved in trials of PCSK9 inhibitors. In this state of the art review, we aimed to finally justify the critical need for LDL-C reduction to very low levels in secondary prevention patients in order to be as low as possible, as early as possible, and preferably lifelong.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | 1102 Cardiorespiratory Medicine and Haematology |
| Subjects: | R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine R Medicine > RS Pharmacy and materia medica |
| Divisions: | Pharmacy & Biomolecular Sciences |
| Publisher: | Elsevier |
| Related URLs: | |
| Date Deposited: | 05 Mar 2021 12:24 |
| Last Modified: | 28 Dec 2021 00:50 |
| DOI or ID number: | 10.1016/j.pcad.2020.12.008 |
| URI: | https://researchonline.ljmu.ac.uk/id/eprint/14560 |
 |
View Item |